A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Welcome to Morningstar.co.uk!
You have been redirected here from Hemscott.com as we are merging our websites to provide you with a one-stop shop for all your investment research needs.
Get Started: To search for a security, type the name or ticker in the search box at the top of the page and select from the dropdown results.
Registered Hemscott users can log in to Morningstar using the same login details. Similarly, if you are a Hemscott Premium user, you now have a Morningstar Premium account which you can access using the same login details.
Omega Notes CE Mark For Mologic s Rapid Covid-19 Test
Thu, 24th Dec 2020 13:00
(Alliance News) - Omega Diagnostics Group PLC on Thursday said Mologic Ltd has received a CE mark for its professional-use Covid-19 rapid antigen test.
Back in June, the London-listed medical diagnostics company signed a material transfer agreement with Mologic providing access to raw materials and know-how to manufacture the lateral flow antigen test.
The test will provide healthcare professionals an accurate detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.
As announced at its interim results in November, Omega has now established its technology transfer team and looks forward to giving an update in the new year on how the technology transfer and CE Mark is going, so the company can sell the rapid test under Omega s Visitect brand.